The biochemical basis of disease

Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice
Hofmann, I., Geer, M.J., Vögtle, T., Crispin, A., Campagna, D.R., Barr, A.J., Calicchio, M.L., Heising, S., van Geffen, J.P., Kuijpers, M.J.E., Heemskerk, J.W.M., Eble, J.A., Schmitz-Abe, K., Obeng, E.A., Douglas, M., Freson, K., Pondarré, C., Favier, R., Jarvis, G.E., Markianos, K., Turro, E., Ouwehand, W.H., Mazharian, A., Fleming, M.D. and Senis, Y. 2018. Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice. Blood. 132, pp. 1399-1412. doi:10.1182/blood-2017-08-802769

Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out?
Senis, Y. A. and Barr, A.J. 2018. Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out? Molecules. 23 (3), pp. 569-585. doi:10.3390/molecules23030569

Defining the molecular basis of interaction between R3 receptor-type protein tyrosine phosphatases and VE-cadherin
Dorofejeva, O. and Barr, A.J. 2017. Defining the molecular basis of interaction between R3 receptor-type protein tyrosine phosphatases and VE-cadherin. PLoS ONE. 12 (9 : e0184574.), pp. 1-23. doi:10.1371/journal.pone.0184574

Automatic Selection of Molecular Descriptors using Random Forest: Application to Drug Discovery
Cano, G., Garcia-Rodriguez, J., Garcia-Garcia, A, Perez-Sanchez, H., Benediktsson, J.A., Thapa, A. and Barr, A.J. 2016. Automatic Selection of Molecular Descriptors using Random Forest: Application to Drug Discovery. Expert Systems with Applications. 72, pp. 151-159. doi:10.1016/j.eswa.2016.12.008

Recombinant baculovirus receptor systems to study receptor/G-protein communication
Windh, R., Barr, A.J. and Manning, D. 2000. Recombinant baculovirus receptor systems to study receptor/G-protein communication. in: Kenakin, T. and Angus, J. (ed.) The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems Berlin, Germany Springer-Verlag. pp. 335-362

Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention
Butterworth, S., Overduin, M. and Barr, A.J. 2014. Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention. Future Medicinal Chemistry. 6 (12), pp. 1423-1437. doi:10.4155/fmc.14.88

Functional Studies On Receptor-Type Protein Tyrosine Phosphatases Of The R3 Subgroup Using Bimolecular Fluorescence Complementation (BiFC) Assays
Dorofejeva, O., Dwek, M. and Barr, A.J. 2014. Functional Studies On Receptor-Type Protein Tyrosine Phosphatases Of The R3 Subgroup Using Bimolecular Fluorescence Complementation (BiFC) Assays . Pharmacology 2014. London 16 Dec 2014 British Pharmacological Society.

Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention
Butterworth, S., Overduin, M. and Barr, A.J. 2014. Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention. Future Medicinal Chemistry. 6 (12), pp. 1423-1437. doi:10.4155/fmc.14.88

Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states
Shintre, C.A., Pike, A.C.W., Li, Q., Kim, J.I., Barr, A.J., Goubin, S., Shrestha, L., Yang, J., Berridge, G., Ross, J., Stansfeld, P.J., Sansom, M.S.P., Edwards, A.M., Bountra, C., Marsden, B., von Delft, F., Bullock, A.N., Gileadi, O., Burgess-Brown, N.A. and Carpenter, E.P. 2013. Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states. Proceedings of the National Academy of Sciences. 110 (24), pp. 9710-9715. doi:10.1073/pnas.1217042110

Receptor tyrosine phosphatase PTPγ is a regulator of spinal cord neurogenesis
Hashemia, H., Hurley, M., Gibson, A., Panova, V., Tchetchelnitski, V., Barr, A.J. and Stoker, A.W. 2011. Receptor tyrosine phosphatase PTPγ is a regulator of spinal cord neurogenesis. Molecular and Cellular Neuroscience. 46 (2), pp. 469-482. doi:10.1016/j.mcn.2010.11.012

Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class
Salah, E., Ugochukwu, E., Barr, A.J., von Delft, F., Knapp, S. and Elkins, J.M. 2011. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. Journal of Medicinal Chemistry. 54 (7), pp. 2359-2367. doi:10.1021/jm101506n

Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development
Barr, A.J. 2010. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Medicinal Chemistry. 2 (10), pp. 1563-1576. doi:10.4155/fmc.10.241

CD148 enhances platelet responsiveness to collagen by maintaining a pool of active Src family kinases
Ellison, S., Mori, J., Barr, A.J. and Senis, Y.A. 2010. CD148 enhances platelet responsiveness to collagen by maintaining a pool of active Src family kinases. Journal of Thrombosis and Haemostasis. 8 (7), pp. 1575-1583. doi:10.1111/j.1538-7836.2010.03865.x

Large-scale structural analysis of the classical human protein tyrosine phosphatome
Barr, A.J., Ugochukwu, E., Lee, W.H., King, O.N.F., Filippakopoulos, P., Alfano, I., Savitsky, P., Burgess-Brown, N.A., Muller, S. and Knapp, S. 2009. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell. 136 (2), pp. 352-363. doi:10.1016/j.cell.2008.11.038

HD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain
Gingras, M.C., Zhang, Y.L., Kharitidi, D., Barr, A.J., Knapp, S., Tremblay, M.L. and Pause, A. 2009. HD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain. PLoS ONE. Online.

Large scale structural analysis of protein tyrosine phosphatases
Barr, A.J. and Knapp, S. 2009. Large scale structural analysis of protein tyrosine phosphatases. in: Bradshaw, R. and Dennis, E. (ed.) Handbook of cell signaling (2nd edition) San Diego, CA Elsevier. pp. 871-876

Sequence-specific 1H, 13C and 15N backbone resonance assignments of the 34 kDa catalytic domain of human PTPN7
Jeeves, M., McClelland, D.M., Barr, A.J. and Overduin, M. 2008. Sequence-specific 1H, 13C and 15N backbone resonance assignments of the 34 kDa catalytic domain of human PTPN7. Biomolecular NMR Assignments. 2 (2), pp. 101-103. doi:10.1007/s12104-008-9095-7

MAPK-specific tyrosine phosphatases: new targets for drug discovery?
Barr, A.J. and Knapp, S. 2006. MAPK-specific tyrosine phosphatases: new targets for drug discovery? Trends in Pharmacological Sciences. 27 (10), pp. 525-530. doi:10.1016/j.tips.2006.08.005

The crystal structure of human receptor protein tyrosine phosphatase κ phosphatase domain 1
Eswaran, J., Debreczeni, J.E., Longman, E., Barr, A.J. and Knapp, S. 2006. The crystal structure of human receptor protein tyrosine phosphatase κ phosphatase domain 1. Protein Science. 15 (6), pp. 1500-1505. doi:10.1110/ps.062128706

Crystal structure of human protein tyrosine phosphatase 14 (PTPN14) at 1.65-A resolution
Barr, A.J., Debreczeni, J.E., Eswaran, J. and Knapp, S. 2006. Crystal structure of human protein tyrosine phosphatase 14 (PTPN14) at 1.65-A resolution. Proteins. 63 (4), pp. 1132-1136. doi:10.1002/prot.20958

Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases
Eswaran, J., von Kries, J.P., Marsden, B., Longman, E., Debreczeni, J.E., Ugochukwu, E., Turnbull, A., Lee, W.H., Knapp, S. and Barr, A.J. 2006. Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases. Biochemical Journal. 395 (3), pp. 483-491. doi:10.1042/BJ20051931

Phospholipase C-β 2 interacts with mitogen-activated protein kinase kinase 3
Barr, A.J., Marjoram, R.J., Xu, J. and Snyderman, R. 2002. Phospholipase C-β 2 interacts with mitogen-activated protein kinase kinase 3. Biochemical and Biophysical Research Communications. 293 (1), pp. 647-652. doi:10.1016/S0006-291X(02)00259-0

RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses
Richardson, R.M., Marjoram, R.J., Barr, A.J. and Snyderman, R. 2001. RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses. Biochemistry. 40 (12), pp. 3583-3588. doi:10.1021/bi0019242

Recombinant baculovirus receptor systems to study receptor/G-protein communication
Windh, R., Barr, A.J. and Manning, D.R. 2000. Recombinant baculovirus receptor systems to study receptor/G-protein communication. in: Kenakin, T. and Angus, J.A. (ed.) The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems Berlin Heidelberg Springer. pp. 335-362

Function and regulation of chemoattractant receptors
Haribabu, B., Richardson, R.M., Verghese, M.W., Barr, A.J., Zhelev, D.V. and Snyderman, R. 2000. Function and regulation of chemoattractant receptors. Immunologic Research. 22 (2-3), pp. 271-279. doi:10.1385/IR:22:2-3:271

Identification of a region at the N-terminus of phospholipase C-beta 3 that interacts with G protein beta gamma subunits
Barr, A.J., Ali, H., Haribabu, B., Snyderman, R. and Smrcka, A.V. 2000. Identification of a region at the N-terminus of phospholipase C-beta 3 that interacts with G protein beta gamma subunits. Biochemistry. 39 (7), pp. 1800-1806. doi:10.1021/bi992021f

Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the Gi, Gq, and G12 families of heterotrimeric G proteins
Windh, R., Lee, M.J., Hla, T., An, S., Barr, A.J. and Manning, D.R. 1999. Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the Gi, Gq, and G12 families of heterotrimeric G proteins. Journal of Biological Chemistry. 274 (39), pp. 27351-27358. doi:10.1074/jbc.274.39.27351

Agonist-promoted GTP[S35]-binding as a probe for receptor.G protein communication in Sf9 cells
Barr, A.J. and Manning, D.R. 1999. Agonist-promoted GTP[S35]-binding as a probe for receptor.G protein communication in Sf9 cells. in: Manning, D.R. (ed.) G proteins: techniques of analysis Boca Raton, FL CRC Press. pp. 227-246

Differential regulation of formyl peptide and platelet-activating factor receptors: role of phospholipase Cbeta3 phosphorylation by protein kinase A
Ali, H., Sozzani, S., Fisher, I., Barr, A.J., Richardson, R.M., Haribabu, B. and Snyderman, R. 1998. Differential regulation of formyl peptide and platelet-activating factor receptors: role of phospholipase Cbeta3 phosphorylation by protein kinase A. Journal of Biological Chemistry. 273 (18), pp. 11012-11016. doi:10.1074/jbc.273.18.11012

Agonist-independent activation of Gz by the 5-hydroxytryptamine1A receptor co-expressed in spodoptera frugiperda cells: distinguishing inverse agonists from neutral antagonists
Barr, A.J. and Manning, D.R. 1997. Agonist-independent activation of Gz by the 5-hydroxytryptamine1A receptor co-expressed in spodoptera frugiperda cells: distinguishing inverse agonists from neutral antagonists. Journal of Biological Chemistry. 272 (52), pp. 32979-32987. doi:10.1074/jbc.272.52.32979

Reconstitution of receptors and GTP-binding regulatory proteins (G Proteins) in Sf9 Cells: a direct evaluation of selectivity in receptor.G protein coupling
Barr, A.J., Brass, L.F. and Manning, D.R. 1997. Reconstitution of receptors and GTP-binding regulatory proteins (G Proteins) in Sf9 Cells: a direct evaluation of selectivity in receptor.G protein coupling. Journal of Biological Chemistry. 272 (4), pp. 2223-2229. doi:10.1074/jbc.272.4.2223

Protein kinase C mediates delayed inhibitory feedback regulation of human neurokinin type 1 receptor activation of phospholipase C in UC11 astrocytoma cells
Barr, A.J. and Watson, S.P. 1994. Protein kinase C mediates delayed inhibitory feedback regulation of human neurokinin type 1 receptor activation of phospholipase C in UC11 astrocytoma cells. Molecular Pharmacology. 46 (2), pp. 266-273.

Non-peptide antagonists, CP-96,345 and RP 67580, distinguish species variants in tachykinin NK1 receptors
Barr, A.J. and Watson, S.P. 1993. Non-peptide antagonists, CP-96,345 and RP 67580, distinguish species variants in tachykinin NK1 receptors. British Journal of Pharmacology. 108 (1), pp. 223-227.

The presence of NK3 tachykinin receptors on rat uterus
Barr, A.J., Watson, S.P., Bernal, A.L. and Nimmo, A.J. 1991. The presence of NK3 tachykinin receptors on rat uterus. European Journal of Pharmacology. 203 (2), pp. 287-290. doi:10.1016/0014-2999(91)90726-7